Scandion Oncology AS (OSTO:SCOL) COGS-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS COGS-to-Revenue?

Scandion Oncology AS's Cost of Goods Sold for the three months ended in Dec. 2024 was kr0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was kr0.00 Mil.

Scandion Oncology AS's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Scandion Oncology AS's Gross Margin % for the three months ended in Dec. 2024 was N/A%.

Scandion Oncology AS COGS-to-Revenue Historical Data

The historical data trend for Scandion Oncology AS's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS COGS-to-Revenue Chart

Scandion Oncology AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

Scandion Oncology AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Scandion Oncology AS COGS-to-Revenue Calculation

Scandion Oncology AS's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Scandion Oncology AS's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Scandion Oncology AS (OSTO:SCOL) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Scandion Oncology AS's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Scandion Oncology AS COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Scandion Oncology AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

8VY:Germany

Address

Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100

Website

https://www.scandiononcology.com

Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines